Literature DB >> 3584472

Characterization of an abnormal species of apolipoprotein B, apolipoprotein B-37, associated with familial hypobetalipoproteinemia.

S G Young, S J Bertics, L K Curtiss, J L Witztum.   

Abstract

Steinberg and colleagues have previously described a unique kindred with normotriglyceridemic hypobetalipoproteinemia (1979. J. Clin. Invest. 64:292-301). In a reexamination of this kindred, we found an abnormal apolipoprotein (apo) B species, apo B-37 (203,000 mol wt), in the plasma lipoproteins of multiple members of the kindred. In affected individuals apo B-37 was found in very low density lipoproteins, along with the normal apo B species, apo B-100 and apo B-48. High density lipoproteins (HDL) also contained apo B-37, but no other apo B species. The first 13 amino-terminal amino acids of apo B-37 were identical to those of normal apo B-100. We utilized a panel of 18 different apo B-specific monoclonal antibodies and polyclonal antisera specific for apo B-37 and the thrombin cleavage products of apo B-100 to map apo B-37 in relation to apo B-100, apo B-48, and the thrombin cleavage products of apo B-100. The results of those immunochemical studies indicated that apo B-37 contains only amino-terminal domains of apo B-100. In affected individuals, the majority of apo B-37 in plasma was contained in the HDL density fraction. Within that fraction apo B-37 was found on discrete lipoprotein particles, termed Lp-B37, that had properties distinct from normal HDL particles containing apo A-I. This report documents for the first time the existence of an abnormal apo B species in humans. Further study of apo B-37 and lipoprotein particles containing apo B-37 should lead to an improved understanding of apo B structure and function.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3584472      PMCID: PMC424527          DOI: 10.1172/JCI113025

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

Review 2.  Abetalipoproteinemia.

Authors:  H J Kayden
Journal:  Annu Rev Med       Date:  1972       Impact factor: 13.739

3.  Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons.

Authors:  J P Kane; D A Hardman; H E Paulus
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

4.  Characterization of human high-density lipoproteins by gradient gel electrophoresis.

Authors:  P J Blanche; E L Gong; T M Forte; A V Nichols
Journal:  Biochim Biophys Acta       Date:  1981-09-24

5.  Purification and quantitation of the human plasma lipoprotein carrying the Lp(a) antigen.

Authors:  C Ehnholm; H Garoff; K Simons; H Aro
Journal:  Biochim Biophys Acta       Date:  1971-05-25

6.  Immunoassay of human plasma apolipoprotein B.

Authors:  J J Albers; V G Cabana; W R Hazzard
Journal:  Metabolism       Date:  1975-12       Impact factor: 8.694

7.  Metabolic studies in an unusual case of asymptomatic familial hypobetalipoproteinemia with hypolphalipoproteinemia and fasting chylomicronemia.

Authors:  D Steinberg; S M Grundy; H Y Mok; J D Turner; D B Weinstein; W V Brown; J J Albers
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

Review 8.  Hypolipidemia.

Authors:  M J Malloy; J P Kane
Journal:  Med Clin North Am       Date:  1982-03       Impact factor: 5.456

9.  Assay of total plasma apolipoprotein B concentration in human subjects.

Authors:  G Schonfeld; R S Lees; P K George; B Pfleger
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

10.  Normotriglyceridemic abetalipoproteinemia. absence of the B-100 apolipoprotein.

Authors:  M J Malloy; J P Kane; D A Hardman; R L Hamilton; K B Dalal
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

View more
  22 in total

Review 1.  Genetic basis of lipoprotein disorders.

Authors:  J L Breslow
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 2.  Control of protein topology at the endoplasmic reticulum.

Authors:  V R Lingappa
Journal:  Cell Biophys       Date:  1991 Oct-Dec

3.  Inference of a molecular defect of apolipoprotein B in hypobetalipoproteinemia by linkage analysis in a large kindred.

Authors:  M Leppert; J L Breslow; L Wu; S Hasstedt; P O'Connell; M Lathrop; R R Williams; R White; J M Lalouel
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

4.  Genetic evidence from two families that the apolipoprotein B gene is not involved in abetalipoproteinemia.

Authors:  P J Talmud; J K Lloyd; D P Muller; D R Collins; J Scott; S Humphries
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

5.  A genetic model for absent chylomicron formation: mice producing apolipoprotein B in the liver, but not in the intestine.

Authors:  S G Young; C M Cham; R E Pitas; B J Burri; A Connolly; L Flynn; A S Pappu; J S Wong; R L Hamilton; R V Farese
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

6.  Familial hypobetalipoproteinemia caused by a mutation in the apolipoprotein B gene that results in a truncated species of apolipoprotein B (B-31). A unique mutation that helps to define the portion of the apolipoprotein B molecule required for the formation of buoyant, triglyceride-rich lipoproteins.

Authors:  S G Young; S T Hubl; R S Smith; S M Snyder; J F Terdiman
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

7.  Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation.

Authors:  M F Linton; R Gish; S T Hubl; E Bütler; C Esquivel; W I Bry; J K Boyles; M R Wardell; S G Young
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

8.  Genetic analysis of a kindred with familial hypobetalipoproteinemia. Evidence for two separate gene defects: one associated with an abnormal apolipoprotein B species, apolipoprotein B-37; and a second associated with low plasma concentrations of apolipoprotein B-100.

Authors:  S G Young; S J Bertics; L K Curtiss; B W Dubois; J L Witztum
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

9.  Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding.

Authors:  T L Innerarity; K H Weisgraber; K S Arnold; R W Mahley; R M Krauss; G L Vega; S M Grundy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

10.  Targeted modification of the apolipoprotein B gene results in hypobetalipoproteinemia and developmental abnormalities in mice.

Authors:  G E Homanics; T J Smith; S H Zhang; D Lee; S G Young; N Maeda
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.